Speaker Profile
Biography
Dr. Bick is a physician-scientist working in the field of human genomics. His scientific observations have advanced our understanding of the genetic basis for cardiovascular disease, characterized molecular disease mechanisms and identified both the promise and limitations of translating genomic findings into routine medical practice. He has a particular interest in understanding how the interplay between inherited germline genetic factors and acquired somatic mutations contributes to disease. His approach has been highly collaborative and multidisciplinary – combining human genomics and statistical genetics with in-vitro and in-vivo characterization of model systems and human samples.
Dr Bick’s current scientific focus is on clonal hematopoiesis, a unifying feature of aging diseases as diverse as cardiovascular disease and cancer. He has recently demonstrated that clonal hematopoiesis is virtually absent in adults under 40, but found in >10% of adults over 70 and confers a 10-fold increased risk of blood cancers, 2-fold increased risk of heart attack and 1.5-fold increased risk of death. Dr. Bick is focused on identifying the causes and consequences of clonal hematopoiesis with a goal of developing new treatments targeting clonal hematopoiesis.
In parallel with his research, Dr. Bick completed clinical training in Internal Medicine at Massachusetts General Hospital with a specialization in genomic medicine. He looks forward to seeing patients in the Vanderbilt Genomics and Therapeutics Clinic and aims to translate what is learned from his research studies back to the care of his patients.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Nir Barzilai, Albert Einstein & Mike Snyder, Stanford
PMWC Award Ceremony
• Alexander (Zan) Fleming, Hevolution Foundation (Pioneer)
• Daniel Drucker, Sinai Health (Pioneer)
• Andrea Maier, NUS Yong Loo Lin School of Medicine (Luminary)
Featured Speakers
• Nir Barzilai, Albert Einstein
• Mike Snyder, Stanford
• Andrea Maier, NUS Yong Loo Lin School of Medicine
• Sara Espinoza, Cedars-Sinai
• Brian Kennedy, Buck Institute
• John Newman, Buck Institute / UCSF
• Marco Quarta, Rubedo Life Sciences
• Maria Dermit, Novo Nordisk
• Alan Shuldiner, Regeneron
• David Furman, Stanford
• Steve Horvath, UCLA
• Daniel Belsky, Columbia
• Ahmed Metwally, Google
• Lee Hood, Phenome Health / ISB
• George Slavich, UCLA
Targeting Aging Biology
What is actually druggable today, and what remains wishful thinking.
From Metabolism to Longevity: GLP-1 and Beyond
Incretins reshaping cardiometabolic prevention and healthy aging.
Which Aging Measures Matter?
Biological-age measures and biomarkers that can change clinical decisions.
Wearables & Digital Biomarkers at Scale
Continuous phenotyping and longitudinal signals in real-world aging.
Clinical Translation
Trials, endpoints, regulation, and the hard road to credible longevity medicine.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
Day 1 / Wed · Jan 27
Day 2 / Thu · Jan 28
Day 3 / Fri · Jan 29
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.